news aktuell GmbH

Roger Waters fights back

Share
Roger Waters defends freedom of speech and takes legal action against proposed concert cancellations in Frankfurt and Munich.

(London, United Kingdom): In February 2023, the Hessian State Government and then the Magistrate of the City of Frankfurt announced their extraordinary and prejudicial intention to cancel a concert scheduled to be performed by Roger Waters at the Festhalle in Frankfurt on 28 May. On 28 February 2023, a motion was introduced in the Munich City Council to cancel the concert scheduled for 21 May 2023, in the Munich Olympiahalle. These actions are unconstitutional, without justification, and based upon the false accusation that Roger Waters is antisemitic, which he is not. 

As a result of this unilateral, politically motivated action, Mr Waters has instructed his lawyers to immediately take all necessary steps to overturn this unjustifiable decision to ensure that his fundamental human right of freedom of speech is protected and that all of those who wish to see him perform, are free to do so in Frankfurt, Munich and in any other city in any other country. 

Mr Waters believes that if this blatant attempt to silence him is left unchallenged it could have serious, far-reaching consequences for artists and activists all over the world.

Publisher:
Mark Fenwick Management – London
on behalf of Mr George Roger Waters

Contacts

Press Contact:
HÖCKER Rechtsanwälte PartGmbB
Rechtsanwalt Prof. Dr. Ralf Höcker
Rechtsanwalt Michael Fengler
Friesenplatz 1
50672 Köln
Germany
E-Mail: contact@hoecker.eu
Tel: +49(0)221-93319-10
Fax: +49(0)221-93319-110

About news aktuell GmbH

news aktuell GmbH
news aktuell GmbH
Mittelweg 144
20148 Hamburg

+49 (0)40 4113-32589http://www.newsaktuell.de

news aktuell, a subsidiary of the Deutsche Presse-Agentur (dpa), provides companies, institutions and associations with effective access to both the media and consumers and supports the organizations in telling their stories easily and successfully. Utilizing the digital tools “ots” and “zimpel” PR content reaches all media formats, including classic print titles, wide-reach online portals or social networks. In addition, news aktuell publishes all of its clients' PR content on www.presseportal.de, one of Germany's widest-reaching PR portals. Thus, all relevant multipliers are reached worldwide, ranging from editors and digital influencers to specialist bloggers and interested consumers. Communications specialists from all over Germany rely on the expertise of the dpa subsidiary. news aktuell has been on the market since 1989 and employs over 135 people. The company is based in Hamburg. Further locations include Berlin, Frankfurt and Munich.

Subscribe to releases from news aktuell GmbH

Subscribe to all the latest releases from news aktuell GmbH by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from news aktuell GmbH

Prof Dr Klemens Joos back as CEO of the EUTOP Group14.5.2025 13:27:53 CEST | Press release

Brussels - Prof Dr Klemens Joos (56) has been back at the helm of the EUTOP Group as CEO since 13 May 2025. The background to this is an ambitious growth strategy up to 2035 for the EUTOP Group, which he founded in 1990 while studying business administration at the Ludwig Maximilian University (LMU) in Munich. Just one year after its foundation, the company had a representative office in Brussels. Today, the EUTOP Group has subsidiaries or representative offices in the capitals of all major European Union member states in addition to Brussels. Prof Dr Klemens Joos is also an honorary professor of ‘Business Administration - Political Stakeholder Management’ at the Technical University of Munich (TUM). Enquiries & Contact: Press department EUTOP Group +49 89 323700-0 eutop@eutop.eu

Biomay Launches FDA-Grade CRISPR/Cas9 Nuclease for Off-the-Shelf Purchase9.5.2025 12:00:00 CEST | Press release

(Vienna, Austria) Biomay, a leading manufacturer of recombinant proteins, today announced the commercial availability of its CRISPR/Cas9 nuclease, marking a significant addition to its off-the-shelf product portfolio for genome-editing applications. Clients purchasing Biomay´s Cas9 will benefit from the company´s unparalleled track record and expertise as a market-registered GMP-manufacturer of the nuclease. Biomay is the FDA-approved manufacturer of recombinant Cas9 as the essential component of CASGEVY®, the very first CRISPR genome editing product on the market. Biomay’s Cas9 (internal code “BMC9”) is based on the classical wild-type Cas9 nuclease from Streptococcus pyogenes. The Cas9 manufacturing process has been de novo developed, GMP-implemented and PPQ-validated by Biomay. GMP and RUO manufacturing is performed by fermentation with E. coli and by purification with chromatographic methods. By quality control with a comprehensive set of validated analytical assays, the consistent

mAInthink GmbH: Technological Breakthrough: Hallucination-Free Superintelligence Achieves 99.99% Strategic Accuracy – Germany Gains Permanent Strategic Superiority9.5.2025 10:57:00 CEST | Press release

Worms, May 9, 2025 – The mAInthink GmbH has achieved a technological breakthrough that redefines the future of strategic decision-making: With the development of StratePlan, a hallucination-free superintelligence delivering verified 99.99% strategic accuracy, Germany secures permanent technological, economic, and geopolitical superiority – operationally deployable and scientifically validated.

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye